Docbot has raised $4.0M across 1 funding round.
Key people at Docbot.
Docbot was founded by Andrew Ninh (Founder) and Tyler Dao (Founder) and William Karnes (Founder).
Docbot has raised $4.0M in total across 1 funding round.
Key people at Docbot.
Docbot, Inc. is an artificial intelligence (AI) technology company specializing in gastrointestinal (GI) disease. It develops AI-powered software built on the UltivisionAI platform that provides real-time image analysis, automated reporting, and analytic tools aimed at improving patient care and clinical workflows in GI medicine. Docbot’s products primarily serve physicians by automating patient intake, screening questionnaires, and clinical note generation, addressing inefficiencies in GI diagnostics and care delivery. The company has demonstrated strong growth momentum, having secured seed funding and participated in prestigious accelerators like Y Combinator, positioning itself as an innovator in AI-assisted GI healthcare[1][2][3][5].
Founded around 2018, Docbot emerged from the University of California, Irvine (UCI) ecosystem, initially incubated at UCI Beall Applied Innovation’s Wayfinder program. The founding team leveraged AI predictive technology to detect polyps in real time, a critical advancement for GI disease diagnosis and prevention. Early traction included acceptance into Y Combinator in 2019, raising over $2 million in seed funding, and recognition as an innovator by the Orange County Business Journal. In 2021, Andrew Ritter, an experienced biotech entrepreneur with a background in gut microbiome therapeutics, joined as CEO to lead commercialization and Series A fundraising efforts[3].
Docbot rides the growing trend of AI integration into healthcare, particularly in medical imaging and workflow automation. The timing is favorable due to increasing demand for efficient, accurate diagnostics amid rising GI disease prevalence and healthcare cost pressures. Advances in AI and machine learning enable real-time image analysis that was previously impossible, positioning Docbot to influence clinical practice standards and improve patient outcomes. By automating routine tasks, Docbot also addresses physician burnout, a critical issue in healthcare. Its success contributes to the broader ecosystem by validating AI’s role in specialty medicine and encouraging further innovation in AI-driven diagnostics[1][3].
Looking ahead, Docbot is poised to expand its market presence through commercialization and additional funding rounds. Trends such as personalized medicine, AI adoption in clinical settings, and increasing GI disease awareness will shape its trajectory. As regulatory acceptance of AI tools grows, Docbot’s influence could extend beyond GI to other medical imaging domains. Continued innovation and strategic partnerships will be key to scaling impact. Overall, Docbot exemplifies how focused AI startups can transform specialty healthcare by combining deep domain knowledge with cutting-edge technology, promising significant improvements in patient care and clinical efficiency[3].
Docbot was founded by Andrew Ninh (Founder) and Tyler Dao (Founder) and William Karnes (Founder).
Docbot has raised $4.0M in total across 1 funding round.
Docbot's investors include Bessemer Venture Partners, Expert Dojo, Incisive Ventures, Khosla Ventures, Mayfield, Scale Asia Ventures, The Valley Fund, Think + Ventures, Ankush Gera, Kunal Shah.
Docbot has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $4.0M Series A | Bessemer Venture Partners, Expert Dojo, Incisive Ventures, Khosla Ventures, Mayfield, Scale Asia Ventures, The Valley Fund, Think + Ventures, Ankush Gera, Kunal Shah |
